In re: Valsartan Products Liability Litigation

Valsartan - Drug Image.jpg

The Valsartan litigation

In July 2018, the FDA issued a press release announcing the voluntary recall of several high-blood pressure medications which contain Valsartan, due to the presence of N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) found in the active ingredient in the drugs. The EPA lists NDMA and NDEA as probable human carcinogens.

Since the recall in 2018, various lawsuits for personal injury and economic loss have been brought against the manufacturers, distributors, wholesalers, and retailers of Valsartan products. Many of these lawsuits have been consolidated in the case styled In re: Valsartan Products Liability Litigation which is in the United States District Court for the District of New Jersey, Case No. 1:19-md-02875. Further, the voluntary recall has expanded to include the related drug medications: Amlodipine, Irbesartan, and Losartan.

the law offices of george a. barton

Stacy Burrows, Senior Associate, is actively litigating the case as a Member of the Plaintiffs Steering Committee. In addition, Ms. Burrows is a Member on the Consumer Class Committee and the Discovery Committee.

The Law Offices of George A. Barton, P.C. is committed to zealously pursing the rights and claims of individuals affected by the Valsartan recall. If you have taken any of the recalled medications, you may need to take action to protect your rights and claims. Below are helpful links containing certain information regarding the In re: Valsartan Products Liability Litigation.

First FDA Press Release

List of Valsartan, Amlodipine, Irbesartan, and Losartan Recalled Medication as of July 26, 2019

Economic Loss Class Action Complaint

Personal Injury Complaint